Beacon Cell Therapy Database

Give your cell therapy molecular design the best chance of success for a given target & indication, with the ability to breakdown the landscape & identify the competitive landscape by cell source, cell type, armouring, costimulatory domains, HLA subtypes, MHS restrictions, editing technology therapeutic class & beyond.

Beacon has 20+ cell therapy technology search filters allowing the most comprehensive & granular searching to narrow down thousands of cell therapies to niche areas of competition, providing confidence to your decision making & ensuring you can select the right technologies & progress meaningful pipeline with a clear path to market.

Use a combination of Beacon’s proprietary cell therapy filters to search for armoring approaches including chemokines, interleukins, antibodies, enzymes, gene knockdown/knockout & many more to identify how to optimize your cell therapy molecular design, with a wealth of technology data captured.

Access comprehensive & meticulously curated scientific data from discovery & preclinical through to approved drugs to inform your understanding of what edits have demonstrated increased efficacy & durability, with the ability to quickly filter programs that released this data & streamline your workflows.

Navigate searching the global trial landscape using Beacon’s proprietary cell therapy searching filters, allowing targeted searches based on cell therapy technologies, location, phase, indication & beyond to rapidly identify which trials have relevant insights to help shape your own strategy.

Track cell therapy clinical developments through to approvals with a market leading curation of clinical data points by a team of cell therapy researchers, segmenting clinical readouts into drug dosing, patient data, toxicity, immunogenicity & CRS data, clinical results lymphodepletion & preconditioning regimens, overall/partial response & beyond to rapidly understand failed & successful trial strategies which can play an important role in how you design new trials.

Learn more about our Clinical Trial Data curation

With a plethora of new cell therapy preclinical programs entering pipelines, accessing comprehensive data on emerging therapies & identifying the experiments that helped push other cell therapies into clinical trial is becoming more challenging.

Beacon Cell Therapy is unique in the volume of preclinical data sourcing & extent of manual curation, allowing you to access all public readouts across:

• In Vitro Assays
• Efficacy
• PK
• Toxicity
• Animal Models & Cell Lines

Beacon’s advanced filtering allows you to quickly identify which cell therapy programs have released preclinical data before reviewing curated summaries from a team of cell therapy researchers, handwriting key points from conference posters, scientific journals, corporate presentations & 1000s of other sources to confidently give you the full picture when designing your own preclinical program.

Learn More about our Preclinical Drug Data.

Optimize your cell therapy partnership strategy by identifying new prospect companies or competitors as soon as they enter the field, taking advantage of Beacon’s unique approach to capturing early-stage companies & depth of scientific & commercial insight captured.

Searching cell therapy companies & deals by therapeutic class (such as in vivo CAR, CAR-NK, TILs, CAR-T), cell source, cell type, starting material (iPSC, ESC etc.). provides a unique way of identifying companies based on technology overlaps & synergy.

Support partnership outreach & diligence with curated Company Data.

With the level of scrutiny from investors increasing by the day, the ability to answer questions on the competitive landscape & clearly communicate your position against competitors is becoming a non-negotiable.

Beacon cell therapy has all the necessary data you need to feel confident with your investment strategy, with the ability to quickly search for competitors & access in depth curation on scientific readouts & commercial insights from companies who managed to successfully raise similar capital.

Learn More about Beacon’s Deal and Company Data.